Tianjin Medical Journal

Tianjin Medical Journal ›› 2020, Vol. 48 ›› Issue (6): 567-571.

Previous Articles     Next Articles

Research progression in the treatment of breast tumors with Chidamide #br#

ZHI Xiang-cheng, CAO Li-xia, SHI Zhen-dong, LIU Jing-jing, ZHANG Jin△ #br#   

  1. Abstract: Chidamide is the first subtype selective histone deacetylase (HDAC) inhibitor independently developed and synthesized in China, belonging to epigenetic drugs.Histone is one of the basic components of human chromosomes, and its acetylation plays an important role in the development of tumors.Studies have shown that when HDAC is overexpressed in cells, it can lead to an acetylation imbalance, which in turn induces tumorigenesis.Therefore, inhibiting the effect of HDAC has become one of the important approaches of tumor therapy.
  • Received:2019-10-31 Revised:2020-03-16 Published:2020-06-15 Online:2020-06-15

PDF (PC)

2313

PDF (Mobile)

16

Abstract: Chidamide is the first subtype selective histone deacetylase (HDAC) inhibitor independently developed and synthesized in China, belonging to epigenetic drugs.Histone is one of the basic components of human chromosomes, and its acetylation plays an important role in the development of tumors.Studies have shown that when HDAC is overexpressed in cells, it can lead to an acetylation imbalance that can lead to tumorigenesis.Therefore, inhibiting the effect of HDAC has become one of the important approaches of tumor therapy.

Key words: breast neoplasms, histone deacetylase inhibitors, Chidamide, review